Monthly
US$200
Billed every month
Clopidogrel Hydrogen Sulphate Tablets(硫酸氢氯吡格雷片)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders30View records ↓
Under-review filings6View records ↓
This year’s generic filers3View records ↓
NHSA approval numbers37View records ↓
API companies with A status49View records ↓
Chemical-drug catalogue
Loaded records: 30 holders; 3 in the quality-and-efficacy consistency-evaluation category, and 26 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 江苏万高药业股份有限公司 | 江苏万高药业股份有限公司 | 国药准字H20266055 | 2026/09/22 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东泉新泉益药业有限公司 | 广州玻思韬控释药业有限公司 | 国药准字H20265799 | 2026/09/02 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华泰民康（沈阳）科技有限公司 | 苏州特瑞药业股份有限公司 | 国药准字H20264069 | 2026/04/21 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江众延医药科技有限公司 | 青岛黄海制药有限责任公司 | 国药准字H20263695 | 2026/03/25 | 75mg（按C16H16ClNO2S计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南药谷云生物科技有限公司 | 杭州民生药业股份有限公司 | 国药准字H20263415 | 2026/02/10 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 辽宁鑫善源药业有限公司 | 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 2026/01/27 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆药友制药有限责任公司 | 重庆药友制药有限责任公司 | 国药准字H20255204 | 2025/08/26 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 天方药业有限公司 | 天方药业有限公司 | 国药准字H20254305 | 2025/05/27 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川鲁徽制药有限责任公司 | 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 2025/04/01 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 宁波美诺华天康药业有限公司 | 宁波美诺华天康药业有限公司 | 国药准字H20243288 | 2024/02/23 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江京新药业股份有限公司 | 浙江京新药业股份有限公司 | 国药准字H20234617 | 2023/12/05 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 国药集团致君（深圳）制药有限公司 | 国药集团致君（深圳）坪山制药有限公司 | 国药准字H20234612 | 2023/12/05 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 东莞市阳之康医药有限责任公司 | 广东东阳光药业有限公司 | 国药准字H20233888 | 2023/06/30 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 中国台湾培力药品工业股份有限公司 | 中国台湾培力药品工业股份有限公司 | 国药准字 HC20220002 | 2022/07/07 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| Esseti Farmaceutici S.r.l. | Laboratorios Lesvi, S.L. | 国药准字HJ20220005 | 2022/02/11 | 75mg（按C16H16ClNO2S 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京四环制药有限公司 | 北京四环制药有限公司 | 国药准字H20213840 | 2021/11/03 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 扬子江药业集团广州海瑞药业有限公司 | 扬子江药业集团广州海瑞药业有限公司 | 国药准字H20213479 | 2021/06/16 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江和泽医药科技股份有限公司 | 昆山龙灯瑞迪制药有限公司 | 国药准字H20213330 | 2021/05/08 | 75 mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都苑东生物制药股份有限公司 | 成都苑东生物制药股份有限公司 | 国药准字H20203701 | 2020/12/21 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 吉林省博大伟业制药有限公司 | 吉林省博大伟业制药有限公司 | 国药准字H20203667 | 2020/12/11 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 惠州信立泰药业有限公司 | 深圳信立泰药业股份有限公司 | 国药准字H20203616 | 2020/12/02 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 惠州信立泰药业有限公司 | 深圳信立泰药业股份有限公司 | 国药准字H20203637 | 2020/12/02 | 25mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| Hexal AG | Sandoz Private Limited， | 国药准字HJ20200049 | 2020/11/24 | 75 mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南迪诺制药股份有限公司 | 湖南迪诺制药股份有限公司 | 国药准字H20203609 | 2020/11/24 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏联环药业股份有限公司 | 江苏联环药业股份有限公司 | 国药准字H20203534 | 2020/10/27 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| — | 印度瑞迪博士实验室有限公司 | H20180074 | 2020/07/07 | 75mg（按C16H16ClNO2S计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 南京正大天晴制药有限公司 | 南京正大天晴制药有限公司 | 国药准字H20203269 | 2020/06/17 | 75mg（按C16H16ClNO2S计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 深圳信立泰药业股份有限公司 | 深圳信立泰药业股份有限公司 | 国药准字H20120018 | 2020/05/14 | 300mg（按C16H16ClNO2S计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 石药集团欧意药业有限公司 | 石药集团欧意药业有限公司 | 国药准字H20193160 | 2019/05/29 | 75mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| — | 乐普药业股份有限公司 | 国药准字H20123116 | 2018/11/23 | 75mg（以C16H16ClNO2S计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| — | 乐普药业股份有限公司 | 国药准字H20123115 | 2018/11/22 | 25mg（以C16H16ClNO2S计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| — | 深圳信立泰药业股份有限公司 | 国药准字H20000542 | 2018/04/02 | 25mg（按C16H16ClNO2S计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 深圳信立泰药业股份有限公司 | 深圳信立泰药业股份有限公司 | 国药准字H20120035 | 2017/12/27 | 75mg(按C16H16ClNO2S计) | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| Sanofi Clir SNC | Sanofi Winthrop Industrie | H20150256; H20150257; H20150258 | 2010/11/05 | 300mg(以氯吡格雷计) | Imported originator drug (进口原研药品) | CDE |
| Sanofi Clir SNC | Sanofi Winthrop Industrie | H20171237 | 2001/01/22 | 75mg | Imported originator drug (进口原研药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 37 distinct approval numbers and 32 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 山东新华制药股份有限公司 | 国药准字H20213840 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010100153 | NHSA |
| 国药集团致君(深圳)制药有限公司 | 国药准字H20234612 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010100430 | NHSA |
| 深圳信立泰药业股份有限公司 | 国药准字H20120018 | 300mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010100553 | NHSA |
| 扬子江药业集团广州海瑞药业有限公司 | 国药准字H20213479 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010100568 | NHSA |
| 重庆药友制药有限责任公司 | 国药准字H20255204 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010101066 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20203534 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010101467 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20266055 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010101503 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20213330 | 75mg(按C₁₆H₁₆ClNO₂S 计) | Category B (乙) | XB01ACL190A001010101533 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20203269 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010101606 | NHSA |
| 成都苑东生物制药股份有限公司 | 国药准字H20203701 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010102181 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20193160 | 75mg | Category B (乙) | XB01ACL190A001010102770 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20123115 | 25mg(以C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010103094 | NHSA |
| 天方药业有限公司 | 国药准字H20254305 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010103098 | NHSA |
| 海南药谷云生物科技有限公司 | 国药准字H20263415 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010104494 | NHSA |
| 赛诺菲(杭州)制药有限公司 | 国药准字H20056410 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010104502 | NHSA |
| 宁波美诺华天康药业有限公司 | 国药准字H20243288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010104565 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20234617 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010104658 | NHSA |
| 湖南迪诺制药股份有限公司 | 国药准字H20203609 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010104914 | NHSA |
| 东莞市阳之康医药有限责任公司 | 国药准字H20233888 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010106988 | NHSA |
| 吉林省博大伟业制药有限公司 | 国药准字H20203667 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010109639 | NHSA |
| Esseti Farmaceutici S.r.l. | 国药准字HJ20220005 | 75mg(按C16H16ClNO2S 计) | Category B (乙) | XB01ACL190A001010178407 | NHSA |
| HEXAL AG | 国药准字HJ20200049 | 75mg(按C16H16ClN02S计) | Category B (乙) | XB01ACL190A001010178495 | NHSA |
| Actavis Group PTC ehf | H20140965 | 75mg | Category B (乙) | XB01ACL190A001010179040 | NHSA |
| Sanofi Clir SNC | 国药准字J20150111 | 300mg | Category B (乙) | XB01ACL190A001010180426 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010181767 | NHSA |
| 华泰民康(沈阳)科技有限公司 | 国药准字H20264069 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010183344 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010183572 | NHSA |
| Pei Li Pharmaceutical Industrial Co.,Ltd. | 国药准字HC20220002 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010184303 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H20213840 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010200153 | NHSA |
| 国药集团致君(深圳)制药有限公司 | 国药准字H20234612 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010200430 | NHSA |
| 扬子江药业集团广州海瑞药业有限公司 | 国药准字H20213479 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010200568 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20203534 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010201467 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20266055 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010201503 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20213330 | 75mg(按C₁₆H₁₆ClNO₂S 计) | Category B (乙) | XB01ACL190A001010201533 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20203269 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010201606 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20123115 | 25mg(以C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010203094 | NHSA |
| 天方药业有限公司 | 国药准字H20254305 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010203098 | NHSA |
| 海南药谷云生物科技有限公司 | 国药准字H20263415 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010204494 | NHSA |
| 赛诺菲(杭州)制药有限公司 | 国药准字H20056410 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010204502 | NHSA |
| 宁波美诺华天康药业有限公司 | 国药准字H20243288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010204565 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20234617 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010204658 | NHSA |
| 湖南迪诺制药股份有限公司 | 国药准字H20203609 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010204914 | NHSA |
| 东莞市阳之康医药有限责任公司 | 国药准字H20233888 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010206988 | NHSA |
| 吉林省博大伟业制药有限公司 | 国药准字H20203667 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010209639 | NHSA |
| Dr. Reddy's Laboratories Limited | 国药准字HJ20180074 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010278377 | NHSA |
| Esseti Farmaceutici S.r.l. | 国药准字HJ20220005 | 75mg(按C16H16ClNO2S 计) | Category B (乙) | XB01ACL190A001010278407 | NHSA |
| HEXAL AG | 国药准字HJ20200049 | 75mg(按C16H16ClN02S计) | Category B (乙) | XB01ACL190A001010278495 | NHSA |
| Sanofi Winthrop Industrie | 国药准字HJ20171237 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010278814 | NHSA |
| Actavis Group PTC ehf | H20140965 | 75mg | Category B (乙) | XB01ACL190A001010279040 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010281767 | NHSA |
| 华泰民康(沈阳)科技有限公司 | 国药准字H20264069 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010283344 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010283572 | NHSA |
| Pei Li Pharmaceutical Industrial Co.,Ltd. | 国药准字HC20220002 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010284303 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H20213840 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010300153 | NHSA |
| 国药集团致君(深圳)制药有限公司 | 国药准字H20234612 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010300430 | NHSA |
| 扬子江药业集团广州海瑞药业有限公司 | 国药准字H20213479 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010300568 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20203534 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010301467 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20266055 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010301503 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20213330 | 75mg(按C₁₆H₁₆ClNO₂S 计) | Category B (乙) | XB01ACL190A001010301533 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20203269 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010301606 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20193160 | 75mg | Category B (乙) | XB01ACL190A001010302770 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20123115 | 25mg(以C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010303094 | NHSA |
| 天方药业有限公司 | 国药准字H20254305 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010303098 | NHSA |
| 海南药谷云生物科技有限公司 | 国药准字H20263415 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010304494 | NHSA |
| 赛诺菲(杭州)制药有限公司 | 国药准字H20056410 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010304502 | NHSA |
| 宁波美诺华天康药业有限公司 | 国药准字H20243288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010304565 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20234617 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010304658 | NHSA |
| 湖南迪诺制药股份有限公司 | 国药准字H20203609 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010304914 | NHSA |
| 东莞市阳之康医药有限责任公司 | 国药准字H20233888 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010306988 | NHSA |
| 吉林省博大伟业制药有限公司 | 国药准字H20203667 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010309639 | NHSA |
| Dr. Reddy's Laboratories Limited | 国药准字HJ20180074 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010378377 | NHSA |
| HEXAL AG | 国药准字HJ20200049 | 75mg(按C16H16ClN02S计) | Category B (乙) | XB01ACL190A001010378495 | NHSA |
| Sanofi Winthrop Industrie | 国药准字HJ20171237 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010378814 | NHSA |
| Actavis Group PTC ehf | H20140966 | 75mg | Category B (乙) | XB01ACL190A001010379040 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010381767 | NHSA |
| 华泰民康(沈阳)科技有限公司 | 国药准字H20264069 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010383344 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010383572 | NHSA |
| Pei Li Pharmaceutical Industrial Co.,Ltd. | 国药准字HC20220002 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010384303 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H20213840 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010400153 | NHSA |
| 国药集团致君(深圳)制药有限公司 | 国药准字H20234612 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010400430 | NHSA |
| 扬子江药业集团广州海瑞药业有限公司 | 国药准字H20213479 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010400568 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20203534 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010401467 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20266055 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010401503 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20203269 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010401606 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20193160 | 75mg | Category B (乙) | XB01ACL190A001010402770 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20123115 | 25mg(以C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010403094 | NHSA |
| 天方药业有限公司 | 国药准字H20254305 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010403098 | NHSA |
| 海南药谷云生物科技有限公司 | 国药准字H20263415 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010404494 | NHSA |
| 赛诺菲(杭州)制药有限公司 | 国药准字H20056410 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010404502 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20234617 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010404658 | NHSA |
| 湖南迪诺制药股份有限公司 | 国药准字H20203609 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010404914 | NHSA |
| 东莞市阳之康医药有限责任公司 | 国药准字H20233888 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010406988 | NHSA |
| 吉林省博大伟业制药有限公司 | 国药准字H20203667 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010409639 | NHSA |
| Dr. Reddy's Laboratories Limited | 国药准字HJ20180074 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010478377 | NHSA |
| HEXAL AG | 国药准字HJ20200049 | 75mg(按C16H16ClN02S计) | Category B (乙) | XB01ACL190A001010478495 | NHSA |
| Actavis Group PTC ehf | H20140966 | 75mg | Category B (乙) | XB01ACL190A001010479040 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010481767 | NHSA |
| 华泰民康(沈阳)科技有限公司 | 国药准字H20264069 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010483344 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010483572 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H20213840 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010500153 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20203534 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010501467 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20266055 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010501503 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20203269 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010501606 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20193160 | 75mg | Category B (乙) | XB01ACL190A001010502770 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20123115 | 25mg(以C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010503094 | NHSA |
| 天方药业有限公司 | 国药准字H20254305 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010503098 | NHSA |
| 海南药谷云生物科技有限公司 | 国药准字H20263415 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010504494 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20234617 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010504658 | NHSA |
| 湖南迪诺制药股份有限公司 | 国药准字H20203609 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010504914 | NHSA |
| 东莞市阳之康医药有限责任公司 | 国药准字H20233888 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010506988 | NHSA |
| 吉林省博大伟业制药有限公司 | 国药准字H20203667 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010509639 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010581767 | NHSA |
| 华泰民康(沈阳)科技有限公司 | 国药准字H20264069 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010583344 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010583572 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H20213840 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010600153 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20203534 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010601467 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20203269 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010601606 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20123115 | 25mg(以C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010603094 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20234617 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010604658 | NHSA |
| 湖南迪诺制药股份有限公司 | 国药准字H20203609 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010604914 | NHSA |
| 东莞市阳之康医药有限责任公司 | 国药准字H20233888 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010606988 | NHSA |
| 吉林省博大伟业制药有限公司 | 国药准字H20203667 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010609639 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010681767 | NHSA |
| 华泰民康(沈阳)科技有限公司 | 国药准字H20264069 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010683344 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010683572 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H20213840 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010700153 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20203534 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010701467 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20203269 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010701606 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20123115 | 25mg(以C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010703094 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20234617 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010704658 | NHSA |
| 湖南迪诺制药股份有限公司 | 国药准字H20203609 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010704914 | NHSA |
| 东莞市阳之康医药有限责任公司 | 国药准字H20233888 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010706988 | NHSA |
| 吉林省博大伟业制药有限公司 | 国药准字H20203667 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010709639 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010781767 | NHSA |
| 华泰民康(沈阳)科技有限公司 | 国药准字H20264069 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010783344 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010783572 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20203269 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010801606 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20123115 | 25mg(以C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010803094 | NHSA |
| 湖南迪诺制药股份有限公司 | 国药准字H20203609 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010804914 | NHSA |
| 东莞市阳之康医药有限责任公司 | 国药准字H20233888 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010806988 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010881767 | NHSA |
| 华泰民康(沈阳)科技有限公司 | 国药准字H20264069 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010883344 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010883572 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20203269 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010901606 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20123115 | 25mg(以C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010903094 | NHSA |
| 湖南迪诺制药股份有限公司 | 国药准字H20203609 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001010904914 | NHSA |
| 东莞市阳之康医药有限责任公司 | 国药准字H20233888 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010906988 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010981767 | NHSA |
| 华泰民康(沈阳)科技有限公司 | 国药准字H20264069 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010983344 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001010983572 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20123115 | 25mg(以C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001011003094 | NHSA |
| 湖南迪诺制药股份有限公司 | 国药准字H20203609 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001011004914 | NHSA |
| 东莞市阳之康医药有限责任公司 | 国药准字H20233888 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011006988 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011081767 | NHSA |
| 华泰民康(沈阳)科技有限公司 | 国药准字H20264069 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011083344 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011083572 | NHSA |
| 湖南迪诺制药股份有限公司 | 国药准字H20203609 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001011104914 | NHSA |
| 东莞市阳之康医药有限责任公司 | 国药准字H20233888 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011106988 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011181767 | NHSA |
| 华泰民康(沈阳)科技有限公司 | 国药准字H20264069 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011183344 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011183572 | NHSA |
| 湖南迪诺制药股份有限公司 | 国药准字H20203609 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001011204914 | NHSA |
| 东莞市阳之康医药有限责任公司 | 国药准字H20233888 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011206988 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011281767 | NHSA |
| 华泰民康(沈阳)科技有限公司 | 国药准字H20264069 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011283344 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011283572 | NHSA |
| 东莞市阳之康医药有限责任公司 | 国药准字H20233888 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011306988 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011381767 | NHSA |
| 华泰民康(沈阳)科技有限公司 | 国药准字H20264069 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011383344 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011383572 | NHSA |
| 东莞市阳之康医药有限责任公司 | 国药准字H20233888 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011406988 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011481767 | NHSA |
| 华泰民康(沈阳)科技有限公司 | 国药准字H20264069 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011483344 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011483572 | NHSA |
| 东莞市阳之康医药有限责任公司 | 国药准字H20233888 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011506988 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011581767 | NHSA |
| 华泰民康(沈阳)科技有限公司 | 国药准字H20264069 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011583344 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011583572 | NHSA |
| 东莞市阳之康医药有限责任公司 | 国药准字H20233888 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011606988 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011681767 | NHSA |
| 华泰民康(沈阳)科技有限公司 | 国药准字H20264069 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011683344 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011683572 | NHSA |
| 东莞市阳之康医药有限责任公司 | 国药准字H20233888 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011706988 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011781767 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011783572 | NHSA |
| 东莞市阳之康医药有限责任公司 | 国药准字H20233888 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011806988 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011881767 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011883572 | NHSA |
| 东莞市阳之康医药有限责任公司 | 国药准字H20233888 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011906988 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20263288 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011981767 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001011983572 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001012083572 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001012183572 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001012283572 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001012383572 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001012483572 | NHSA |
| 四川鲁徽制药有限责任公司 | 国药准字H20253784 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001012583572 | NHSA |
| 深圳信立泰药业股份有限公司 | 国药准字H20000542 | 25mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001020100553 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20203534 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001020101467 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20213330 | 75mg(按C₁₆H₁₆ClNO₂S 计) | Category B (乙) | XB01ACL190A001020101533 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20203269 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001020101606 | NHSA |
| 成都苑东生物制药股份有限公司 | 国药准字H20203701 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001020102181 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20193160 | 75mg | Category B (乙) | XB01ACL190A001020102770 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20123116 | 75mg(以C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001020103094 | NHSA |
| 湖南迪诺制药股份有限公司 | 国药准字H20203609 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001020104914 | NHSA |
| Dr. Reddy's Laboratories Limited | 国药准字HJ20180074 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001020178377 | NHSA |
| Sanofi Winthrop Industrie | 国药准字HJ20171237 | 75mg(按C₁₆H₁₆ClNO₂S计) | Category B (乙) | XB01ACL190A001020178814 | NHSA |
| Sanofi-aventis groupe | 国药准字J20180029 | 75mg | Category B (乙) | XB01ACL190A001020180426 | NHSA |
| 深圳信立泰药业股份有限公司 | 国药准字H20000542 | 25mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001020200553 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20213330 | 75mg(按C₁₆H₁₆ClNO₂S 计) | Category B (乙) | XB01ACL190A001020201533 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20123116 | 75mg(以C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001020203094 | NHSA |
| 湖南迪诺制药股份有限公司 | 国药准字H20203609 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001020204914 | NHSA |
| Sanofi-aventis groupe | 国药准字J20180029 | 75mg | Category B (乙) | XB01ACL190A001020280426 | NHSA |
| 深圳信立泰药业股份有限公司 | 国药准字H20000542 | 25mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001020300553 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20123116 | 75mg(以C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001020303094 | NHSA |
| 深圳信立泰药业股份有限公司 | 国药准字H20000542 | 25mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001020400553 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20123116 | 75mg(以C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001020403094 | NHSA |
| 深圳信立泰药业股份有限公司 | 国药准字H20000542 | 25mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001020500553 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20123116 | 75mg(以C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001020503094 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20203269 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001021101606 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20203269 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001021201606 | NHSA |
| 深圳信立泰药业股份有限公司 | 国药准字H20120035 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001030100553 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20203534 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001030101467 | NHSA |
| 成都苑东生物制药股份有限公司 | 国药准字H20203701 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001030102181 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20193160 | 75mg | Category B (乙) | XB01ACL190A001030102770 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20123116 | 75mg(以C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001030103094 | NHSA |
| 湖南迪诺制药股份有限公司 | 国药准字H20203609 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001030104914 | NHSA |
| Sanofi-aventis groupe | 国药准字J20180029 | 75mg | Category B (乙) | XB01ACL190A001030180426 | NHSA |
| 深圳信立泰药业股份有限公司 | 国药准字H20120035 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001030200553 | NHSA |
| 成都苑东生物制药股份有限公司 | 国药准字H20203701 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001030202181 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20123116 | 75mg(以C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001030203094 | NHSA |
| 成都苑东生物制药股份有限公司 | 国药准字H20203701 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001030302181 | NHSA |
| 成都苑东生物制药股份有限公司 | 国药准字H20203701 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001030402181 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20203534 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001030801467 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20203534 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001030901467 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20203534 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001031001467 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20203534 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001031101467 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20203534 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001031201467 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20203534 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001031301467 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20203534 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001031401467 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20203534 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001031501467 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20203534 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001031601467 | NHSA |
| 深圳信立泰药业股份有限公司 | 国药准字H20000542 | 25mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001040100553 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20203534 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001040101467 | NHSA |
| 湖南迪诺制药股份有限公司 | 国药准字H20203609 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001040104914 | NHSA |
| 浙江骏德生物科技有限公司 | 国药准字H20203637 | 25mg(按C₁₆H₁₆CINO₂S计) | Category B (乙) | XB01ACL190A001050100553 | NHSA |
| 浙江骏德生物科技有限公司 | 国药准字H20203637 | 25mg(按C₁₆H₁₆CINO₂S计) | Category B (乙) | XB01ACL190A001050200553 | NHSA |
| 浙江骏德生物科技有限公司 | 国药准字H20203616 | 75mg(按C₁₆H₁₆CINO₂S计) | Category B (乙) | XB01ACL190A001060100553 | NHSA |
| 浙江骏德生物科技有限公司 | 国药准字H20203616 | 75mg(按C₁₆H₁₆CINO₂S计) | Category B (乙) | XB01ACL190A001060200553 | NHSA |
| 浙江骏德生物科技有限公司 | 国药准字H20203616 | 75mg(按C₁₆H₁₆CINO₂S计) | Category B (乙) | XB01ACL190A001070100553 | NHSA |
| 浙江骏德生物科技有限公司 | 国药准字H20203616 | 75mg(按C₁₆H₁₆CINO₂S计) | Category B (乙) | XB01ACL190A001070200553 | NHSA |
| 浙江骏德生物科技有限公司 | 国药准字H20203616 | 75mg(按C₁₆H₁₆CINO₂S计) | Category B (乙) | XB01ACL190A001070300553 | NHSA |
| 浙江骏德生物科技有限公司 | 国药准字H20203616 | 75mg(按C₁₆H₁₆CINO₂S计) | Category B (乙) | XB01ACL190A001070400553 | NHSA |
| 浙江骏德生物科技有限公司 | 国药准字H20203616 | 75mg(按C₁₆H₁₆CINO₂S计) | Category B (乙) | XB01ACL190A001070500553 | NHSA |
| 浙江骏德生物科技有限公司 | 国药准字H20203616 | 75mg(按C₁₆H₁₆CINO₂S计) | Category B (乙) | XB01ACL190A001070600553 | NHSA |
| 浙江骏德生物科技有限公司 | 国药准字H20203616 | 75mg(按C₁₆H₁₆CINO₂S计) | Category B (乙) | XB01ACL190A001070700553 | NHSA |
| 浙江骏德生物科技有限公司 | 国药准字H20203616 | 75mg(按C₁₆H₁₆CINO₂S计) | Category B (乙) | XB01ACL190A001070800553 | NHSA |
| 浙江骏德生物科技有限公司 | 国药准字H20203616 | 75mg(按C₁₆H₁₆CINO₂S计) | Category B (乙) | XB01ACL190A001070900553 | NHSA |
| 浙江骏德生物科技有限公司 | 国药准字H20203616 | 75mg(按C₁₆H₁₆CINO₂S计) | Category B (乙) | XB01ACL190A001071000553 | NHSA |
| 浙江骏德生物科技有限公司 | 国药准字H20203616 | 75mg(按C₁₆H₁₆CINO₂S计) | Category B (乙) | XB01ACL190A001071100553 | NHSA |
| 浙江骏德生物科技有限公司 | 国药准字H20203616 | 75mg(按C₁₆H₁₆CINO₂S计) | Category B (乙) | XB01ACL190A001071200553 | NHSA |
| 浙江骏德生物科技有限公司 | 国药准字H20203616 | 75mg(按C₁₆H₁₆CINO₂S计) | Category B (乙) | XB01ACL190A001071300553 | NHSA |
| 浙江骏德生物科技有限公司 | 国药准字H20203616 | 75mg(按C₁₆H₁₆CINO₂S计) | Category B (乙) | XB01ACL190A001080100553 | NHSA |
| 湖南迪诺制药股份有限公司 | 国药准字H20203609 | 75mg(按C16H16ClNO2S计) | Category B (乙) | XB01ACL190A001040204914 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 6 filings and 5 distinct first applicants.
Generic 5 · Supplement 1
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 浙江诺得药业有限公司 | CYHS2600231 | Generic | 2026/01/20 | Not stated by source | CDE |
| 吉林道君药业股份有限公司;苏州特瑞药业股份有限公司 | CYHS2600700 | Generic | 2026/03/23 | Not stated by source | CDE |
| 四川新斯顿制药股份有限公司 | CYHS2600950 | Generic | 2026/04/24 | Not stated by source | CDE |
| 浙江车头制药股份有限公司;杭州民生药业股份有限公司 | CYHS2504123 | Generic | 2025/12/02 | Not stated by source | CDE |
| 浙江车头制药股份有限公司;杭州民生药业股份有限公司 | CYHS2504122 | Generic | 2025/12/02 | Not stated by source | CDE |
| Actavis Group PTC ehf;Actavis Ltd | JYHB2050004 | Supplement | 2020/09/01 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 3 filings and 3 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 浙江诺得药业有限公司 | CYHS2600231 | Generic | 2026/01/20 | Not stated by source | CDE |
| 吉林道君药业股份有限公司;苏州特瑞药业股份有限公司 | CYHS2600700 | Generic | 2026/03/23 | Not stated by source | CDE |
| 四川新斯顿制药股份有限公司 | CYHS2600950 | Generic | 2026/04/24 | Not stated by source | CDE |
API registrations
Non-component matches: 49 companies with A status and 16 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 硫酸氢氯吡格雷 | IOL Chemicals and Pharmaceuticals Ltd. | Y20240000156 | A | Exact ingredient | 2026/07/14 | CDE |
| 硫酸氢氯吡格雷 | 江西川奇药业有限公司 | Y20230001262 | I | Exact ingredient | 2024/02/08 | CDE |
| 硫酸氢氯吡格雷 | 新天地药业股份有限公司 | Y20230001350 | A | Exact ingredient | 2026/07/07 | CDE |
| 硫酸氢氯吡格雷 | 石家庄中硕制药有限公司 | Y20230001180 | A | Exact ingredient | 2025/08/27 | CDE |
| 硫酸氢氯吡格雷 | 石药集团欧意药业有限公司 | Y20230000554 | A | Exact ingredient | 2024/12/18 | CDE |
| 硫酸氢氯吡格雷 | Dr. Reddy’s Laboratories Ltd. | Y20220000596 | A | Exact ingredient | 2025/04/09 | CDE |
| 硫酸氢氯吡格雷 | Dr. Reddy's Laboratories Ltd. | Y20220000608 | A | Exact ingredient | 2025/04/29 | CDE |
| 硫酸氢氯吡格雷 | Arene Life Sciences Private Limited | Y20220000246 | A | Exact ingredient | 2024/10/24 | CDE |
| 硫酸氢氯吡格雷 | 湖南华纳大药厂手性药物有限公司 | Y20210000940 | A | Exact ingredient | 2023/10/19 | CDE |
| 硫酸氢氯吡格雷 | 山东立新制药有限公司 | Y20210001051 | A | Exact ingredient | 2025/11/07 | CDE |
| 硫酸氢氯吡格雷 | 天津泰普制药有限公司 | Y20210000950 | A | Exact ingredient | 2023/05/05 | CDE |
| 硫酸氢氯吡格雷 | Synthimed Labs Private Limited | Y20210000629 | A | Exact ingredient | 2024/08/23 | CDE |
| 硫酸氢氯吡格雷 | 浙江乐普药业股份有限公司 | Y20200001051 | A | Exact ingredient | 2025/06/26 | CDE |
| 硫酸氢氯吡格雷 | 黑龙江珍宝岛药业股份有限公司鸡西分公司 | Y20210000532 | A | Exact ingredient | 2024/03/29 | CDE |
| 硫酸氢氯吡格雷 | AARTI DRUGS LIMITED | Y20200000957 | I | Exact ingredient | 2021/01/08 | CDE |
| 硫酸氢氯吡格雷 | 浙江燎原药业有限公司 | Y20200000870 | A | Exact ingredient | 2026/10/23 | CDE |
| 硫酸氢氯吡格雷 | 苏州正济药业有限公司 | Y20200000777 | A | Exact ingredient | 2026/01/23 | CDE |
| 硫酸氢氯吡格雷 | 吉林汇康制药有限公司 | Y20200000451 | A | Exact ingredient | 2026/07/27 | CDE |
| 硫酸氢氯吡格雷 | 扬子江药业集团江苏海慈生物药业有限公司 | Y20200000100 | A | Exact ingredient | 2026/04/04 | CDE |
| 硫酸氢氯吡格雷 | 浙江乐普药业股份有限公司 | Y20190001006 | A | Exact ingredient | 2025/07/09 | CDE |
| 硫酸氢氯吡格雷 | 齐鲁制药有限公司 | Y20190009777 | A | Exact ingredient | 2025/11/12 | CDE |
| 硫酸氢氯吡格雷 | 江苏联环药业股份有限公司 | Y20190009735 | A | Exact ingredient | 2025/07/30 | CDE |
| 硫酸氢氯吡格雷 | 四川青木制药有限公司 | Y20190009680 | A | Exact ingredient | — | CDE |
| 硫酸氢氯吡格雷 | 惠州信立泰药业有限公司 | Y20190009462 | A | Exact ingredient | 2024/06/06 | CDE |
| 硫酸氢氯吡格雷 | Assia Chemical Industries Ltd. | Y20190009321 | A | Exact ingredient | 2025/07/03 | CDE |
| 硫酸氢氯吡格雷 | Assia Chemical Industries Ltd. | Y20190009320 | A | Exact ingredient | 2023/03/24 | CDE |
| 硫酸氢氯吡格雷 | RPG Life Sciences Limited | Y20190009092 | A | Exact ingredient | — | CDE |
| 硫酸氢氯吡格雷 | WOCKHARDT LIMITED | Y20190008974 | A | Exact ingredient | — | CDE |
| 硫酸氢氯吡格雷 | WOCKHARDT LIMITED | Y20190008973 | A | Exact ingredient | — | CDE |
| 硫酸氢氯吡格雷 | 绍兴京新药业有限公司 | Y20190008319 | A | Exact ingredient | 2024/02/08 | CDE |
| 硫酸氢氯吡格雷 | 浙江车头制药股份有限公司 | Y20190008314 | A | Exact ingredient | 2026/07/15 | CDE |
| 硫酸氢氯吡格雷 | 天津中瑞药业股份有限公司 | Y20190008288 | A | Exact ingredient | 2024/06/15 | CDE |
| 硫酸氢氯吡格雷 | 苏州正济药业有限公司 | Y20190008280 | A | Exact ingredient | 2024/06/06 | CDE |
| 硫酸氢氯吡格雷 | 石药集团欧意药业有限公司 | Y20190008263 | A | Exact ingredient | — | CDE |
| 硫酸氢氯吡格雷 | 山东新时代药业有限公司 | Y20190008257 | A | Exact ingredient | 2024/01/17 | CDE |
| 硫酸氢氯吡格雷 | 武汉武药制药有限公司 | Y20190008247 | A | Exact ingredient | 2023/03/24 | CDE |
| 硫酸氢氯吡格雷 | 江苏恒瑞医药股份有限公司 | Y20190008241 | A | Exact ingredient | 2023/03/24 | CDE |
| 硫酸氢氯吡格雷 | 浙江华海药业股份有限公司 | Y20190008231 | A | Exact ingredient | 2026/07/03 | CDE |
| 硫酸氢氯吡格雷 | 浙江普洛家园药业有限公司 | Y20190008217 | A | Exact ingredient | 2025/04/24 | CDE |
| 硫酸氢氯吡格雷 | 苏州立新制药有限公司 | Y20190008178 | A | Exact ingredient | 2026/03/03 | CDE |
| 硫酸氢氯吡格雷 | 重庆莱美药业股份有限公司 | Y20190008177 | A | Exact ingredient | — | CDE |
| 硫酸氢氯吡格雷 | 常州制药厂有限公司 | Y20190008090 | A | Exact ingredient | 2025/09/12 | CDE |
| 硫酸氢氯吡格雷 | 苏州天马精细化学品股份有限公司 | Y20190008053 | A | Exact ingredient | — | CDE |
| 硫酸氢氯吡格雷 | 连云港润众制药有限公司 | Y20190007898 | A | Exact ingredient | 2024/03/27 | CDE |
| 硫酸氢氯吡格雷 | 天方药业有限公司 | Y20190007695 | A | Exact ingredient | 2025/07/29 | CDE |
| 硫酸氢氯吡格雷 | 湖南迪诺制药股份有限公司 | Y20190007689 | A | Exact ingredient | 2024/11/26 | CDE |
| 硫酸氢氯吡格雷 | 河南普瑞制药有限公司 | Y20190007688 | A | Exact ingredient | 2024/12/19 | CDE |
| 硫酸氢氯吡格雷 | MSN Organics Private Limited | Y20190000599 | A | Exact ingredient | 2026/09/04 | CDE |
| 硫酸氢氯吡格雷 | 四川青木制药有限公司 | Y20190000408 | A | Exact ingredient | 2025/10/30 | CDE |
| 硫酸氢氯吡格雷 | Aurobindo Pharma Limited | Y20190000321 | I | Exact ingredient | 2019/05/13 | CDE |
| 硫酸氢氯吡格雷（II型） | 苏州立新制药有限公司 | Y20180001218 | A | Exact ingredient | 2026/08/05 | CDE |
| 硫酸氢氯吡格雷 | 江苏联环药业股份有限公司 | Y20180001142 | A | Exact ingredient | 2023/08/01 | CDE |
| 硫酸氢氯吡格雷 | 惠州信立泰药业有限公司 | Y20180001667 | A | Exact ingredient | 2025/12/03 | CDE |
| 硫酸氢氯吡格雷 | 齐鲁制药有限公司 | Y20180001114 | I | Exact ingredient | 2018/09/12 | CDE |
| 硫酸氢氯吡格雷 | 江苏普润生物医药有限公司 | Y20180000992 | A | Exact ingredient | 2024/11/22 | CDE |
| 硫酸氢氯吡格雷 | 浙江乐普药业股份有限公司 | Y20170002277 | A | Exact ingredient | 2022/09/15 | CDE |
| 硫酸氢氯吡格雷 | Dr. Reddy's Laboratories Limited | Y20170001482 | A | Exact ingredient | 2025/07/24 | CDE |
| 硫酸氢氯吡格雷 | 河南润弘制药股份有限公司 | Y20170001392 | I | Exact ingredient | — | CDE |
| 硫酸氢氯吡格雷 | 江西施美制药有限公司 | Y20170001243 | A | Exact ingredient | 2022/10/27 | CDE |
| 硫酸氢氯吡格雷 | 廊坊高博京邦制药有限公司 | Y20170001224 | A | Exact ingredient | 2022/09/30 | CDE |
| 硫酸氢氯吡格雷 | PRAVEEN LABORATORIES PVT. LTD. | Y20170001129 | I | Exact ingredient | — | CDE |
| 硫酸氢氯吡格雷 | 山东威高药业股份有限公司 | Y20170001119 | I | Exact ingredient | — | CDE |
| 硫酸氢氯吡格雷 | 上海现代哈森（商丘）药业有限公司 | Y20170001110 | I | Exact ingredient | — | CDE |
| 硫酸氢氯吡格雷 | 浙江金华康恩贝生物制药有限公司 | Y20170000565 | A | Exact ingredient | 2024/07/31 | CDE |
| 硫酸氢氯吡格雷 | 山东罗欣药业集团股份有限公司 | Y20170000395 | I | Exact ingredient | — | CDE |
| 硫酸氢氯吡格雷 | 吉林省博大伟业制药有限公司 | Y20170000388 | A | Exact ingredient | 2023/08/15 | CDE |
| 硫酸氢氯吡格雷 | 山东齐都药业有限公司 | Y20170000281 | A | Exact ingredient | 2024/02/27 | CDE |
| 硫酸氢氯吡格雷 | 浙江九洲药业股份有限公司 | Y20170000221 | I | Exact ingredient | — | CDE |
| 硫酸氢氯吡格雷 | 广东宏远集团药业有限公司 | Y20170000218 | I | Exact ingredient | — | CDE |
| 硫酸氢氯吡格雷 | 浙江金立源药业有限公司 | Y20170000174 | I | Exact ingredient | — | CDE |
| 硫酸氢氯吡格雷 | 华润双鹤药业股份有限公司 | Y20170000146 | I | Exact ingredient | — | CDE |
| 硫酸氢氯吡格雷 | 天津红日药业股份有限公司 | Y20170000116 | A | Exact ingredient | 2023/12/21 | CDE |
| 硫酸氢氯吡格雷 | 哈尔滨华瑞生化药业有限责任公司 | Y20170000111 | I | Exact ingredient | — | CDE |
| 硫酸氢氯吡格雷 | 浙江江北药业有限公司 | Y20170000089 | I | Exact ingredient | — | CDE |
| 硫酸氢氯吡格雷 | 珠海联邦制药股份有限公司 | Y20170000057 | I | Exact ingredient | — | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/09/01Accepted
重庆华森制药股份有限公司;青岛黄海制药有限责任公司
CYHB2601666
Fact date: 2026/09/01 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Clopidogrel Hydrogen Sulphate Tablets
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy